Join the club for FREE to access the whole archive and other member benefits.

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.

The company's technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.

Previously called Underdog Pharmaceuticals, the company changed its name in 2022.

Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF. 

Visit website: https://underdogpharma.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

See also: Institute SENS Research Foundation - Non-profit organization focused on transforming the way the world researches and treats age-related diseases

People at Cyclarity Therapeutics

Company Representative

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals

Company Representative

Co-Chief Executive Officer and Co-founder of Underdog Pharmaceuticals.

Cyclarity Therapeutics News

Racing for the lead... Underdog becomes Cyclarity Therapeutics

Longevity Technology - 20-Jun-2022

Also announces move to Buck Institute for Research on Aging

Read more...

Underdog pharmaceuticals secures $10m funding from Kizoo ventures

Longevity Technology - 23-Sep-2021

Funds to bring affordable and effective age-related therapies to the public

Read more...

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

Longevity Technology - 09-Sep-2021

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood

Read more...

Two drug molecules delivered via nanoparticles to combat atherosclerosis

Lifespan.io (LEAF) - 26-Jun-2020

Success in mice model gives hope for fighting cholesterol-associated inflammatory diseases

Read more...

Fight Aging! reports back from SENS Research Foundation Pitch Day

Fight Aging! - 20-Jan-2020

When some of these succeed in human trials even more money will pile in to fund further advances

Read more...